# Nuvation Bio

Source: https://onco.cc/companies/nuvation-bio/  
OnCo record `nuvation-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nuvation Bio is a United States-based biotechnology company running 6 late-stage cancer trials of Taletrectinib, AB-106 and NUV-1511 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and prostate cancer.

## Summary

Nuvation Bio, based in New York, NY, the United States, is a biotechnology company. A global oncology company developing therapies for difficult-to-treat cancers; its taletrectinib (IBTROZI) is FDA-approved for ROS1-positive non-small cell lung cancer. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Taletrectinib, AB-106, NUV-1511 and safusidenib in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer. The largest, NCT06334432 (Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumours), plans to enrol 466 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Nuvation Bio Inc.
- Tags: ctgov-sponsor
- HQ: New York, NY
- Type: biotech
- Website: https://www.nuvationbio.com

## Sources

- Official website: https://www.nuvationbio.com
- ClinicalTrials.gov: trials led by Nuvation Bio: https://clinicaltrials.gov/search?lead=Nuvation%20Bio%20Inc.
- Pipeline page: https://www.nuvationbio.com/pipeline

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- drugs: [NUV-1511](https://onco.cc/drugs/nuv-1511/), [Safusidenib](https://onco.cc/drugs/safusidenib/), [Taletrectinib](https://onco.cc/drugs/taletrectinib/)
- trials: [A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients](https://onco.cc/trials/nct06564324/), [A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene](https://onco.cc/trials/nct04395677/), [Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)](https://onco.cc/trials/nct07154706/), [Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06334432/), [SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)](https://onco.cc/trials/nct05303519/), [Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC](https://onco.cc/trials/nct04919811/)

---
JSON: https://onco.cc/api/v1/entities/nuvation-bio.json